- Prescribing Advice for GPs - https://www.prescriber.org.uk -

NICE Guidance - June 2016

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of June 2016. This month there are two technology appraisals that impact upon primary care.

The Alirocumab technology appraisal recommends this treatment as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia only if low‑density lipoprotein concentrations are persistently above the thresholds specified in the appraisal and the manufacturer provides alirocumab with the discount agreed in the patient access scheme.

The Evolocumab technology appraisal recommends this treatment as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia provided the dosage is 140 mg every 2 weeks and only if low‑density lipoprotein concentrations are persistently above the thresholds specified in the appraisal and the manufacturer provides evolocumab with the discount agreed in the patient access scheme.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.